Teva plans to make $7 billion from new medicines by 2030 with a strong focus on research and development.

Nov 11, 2026, 12:39 PM ETResultsRead the original at Benzinga

Good for TEVA

Teva set a $6 billion to $7 billion sales goal for newer medicines by 2030, after sales from them doubled. Cash supports the plan, but some treatments still need approval.

TEVA · Teva Pharmaceutical Industries Ltd.

AI read · Good for TEVA

The AI's read

Teva has already doubled sales from newer medicines and generated more than $6 billion in free cash flow from 2023 to 2025. Late-stage treatments could bring more than $10 billion in peak sales, but regulators still need to approve them. Past growth and cash support the plan, though future launches must succeed.

Get alerts for TEVA

Follow Teva Pharmaceutical Industries Ltd. (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TEVA

Free on the App Store and Google Play, or on the web.